Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Effective Collaboration - Team Research for Better Returns: -- Ignore unavailable to you. Want to Upgrade?

To: RMP who wrote (2387)	7/12/2013 2:56:42 PM
From: The Ox	Respond to of 8288

Thanks, I'll put them in a watch list. If I find some time, I'll check into more of what they do....biotech co....

To: RMP who wrote (2387)	7/12/2013 3:06:34 PM
From: The Ox	Respond to of 8288

Ah, you mentioned them before and I didn't put them into a watch list....shame on me!!

To: RMP who wrote (2387)	8/2/2013 9:23:07 AM
From: The Ox	Read Replies (1) \| Respond to of 8288

Organovo Holdings, Inc. ( ONVO) today announced the sale of 9,000,000 shares of its common stock in an underwritten public offering at a price to the public of $4.50 per share. The net offering proceeds to Organovo from the sale of the shares are expected to be approximately $37.7 million, after deducting underwriting discounts and commissions and other estimated offering expenses, but excluding any exercise of the underwriters' over-allotment option. The Company anticipates using the net proceeds from this offering for general corporate purposes, including research and development, the development and commercialization of its products, general administrative expenses, license or technology acquisitions, and working capital and capital expenditures. The offering is expected to close on or about August 7, 2013, subject to customary closing conditions. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock on the same terms and conditions, solely to cover over-allotments, if any. Lazard Capital Markets LLC and Oppenheimer & Co. Inc. are acting as joint book-runners for the offering. JMP Securities LLC and Maxim Securities LLC are each acting as co-managers for the offering.